Papillary Thyroid Carcinoma in Children: Clinicopathological Profile and Outcomes of Management

被引:9
|
作者
Thomas, John K. [1 ]
Kurian, Jujju Jacob [1 ]
Cherian, Anish Jacob [2 ]
Hephzibah, Julie [3 ]
Paul, M. J. [2 ]
Abraham, Deepak Thomas [2 ]
机构
[1] Christian Med Coll & Hosp, Dept Pediat Surg, Vellore, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Dept Endocrine Surg, Vellore, Tamil Nadu, India
[3] Christian Med Coll & Hosp, Dept Nucl Med, Vellore, Tamil Nadu, India
关键词
PREDICTIVE FACTORS; FOLLOW-UP; ADOLESCENTS; CANCER; RECURRENCE; ESTROGEN; AGE; INSTITUTION; CHILDHOOD; DISEASE;
D O I
10.1007/s00268-020-05817-3
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background We aim to analyze the clinicopathological profile and outcomes of management for children with papillary thyroid carcinoma (PTC). Methods Relevant clinical data of children <= 18 years of age managed for PTC between January 2006 and July 2018 as well as details of their follow-up till December 2019 were retrospectively collected and analyzed. Results There were 82 children with PTC that were managed during the study period. At presentation, 39 (47.6%) had cervical lymphadenopathy, while 9 (11%) had systemic metastasis. Majority of patients 39 (47.6%) underwent total thyroidectomy with a selective neck dissection, while total thyroidectomy alone was performed in 26 (31.7%). Following surgery, hypocalcemia was seen in 39 (47.6%): 28 (34.1%) were temporary, while 11 (13.4%) were permanent. Twenty-eight (34%) developed persistent disease after surgery and(131)I therapy. Significant risk factors for persistence and metastatic disease were metastatic cervical lymph node at presentation (p = 0.002) and tumor size (p = 0.014), respectively. The mean duration of follow-up was 60.3 (range 12-150) months with a mean overall disease-free survival of 60 months (95% CI 57.11, 77.95). Conclusion Children with papillary thyroid cancers present with aggressive disease, 47.6% with cervical nodal metastasis and 11% with distant metastasis in this cohort. The rate of post-thyroidectomy hypocalcemia in this study is substantial, and efforts to reduce it are actively being pursued. The presence of metastatic cervical lymph node at presentation (p = 0.002) and tumor size (p = 0.014) were the only significant risk factors for persistent and metastatic disease, respectively, in this study.
引用
收藏
页码:496 / 506
页数:11
相关论文
共 50 条
  • [31] Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma
    Shoko Kure
    Ryuichi Wada
    Zenya Naito
    Medical Molecular Morphology, 2019, 52 : 181 - 186
  • [32] THE ONCOCYTIC VARIANT OF PAPILLARY CARCINOMA OF THE THYROID - A CLINICOPATHOLOGICAL STUDY OF 15 CASES
    BERHO, M
    SUSTER, S
    LABORATORY INVESTIGATION, 1994, 70 (01) : A51 - A51
  • [33] SKIP METASTASES IN PAPILLARY THYROID CARCINOMA - PREVALENCE, PREDICTIVE AND CLINICOPATHOLOGICAL FACTORS
    Milicic, Borna
    Prstacic, Ratko
    Prgomet, Drago
    ACTA CLINICA CROATICA, 2020, 59 : 122 - 128
  • [34] THYROID REMNANT ABLATION IN CHILDREN WITH PAPILLARY THYROID-CARCINOMA
    ZIMMERMAN, D
    HAY, ID
    BERGSTRALH, EJ
    PEDIATRIC RESEARCH, 1994, 35 (04) : A109 - A109
  • [35] Management dilemma in metastatic papillary thyroid carcinoma
    Patel, Cheerag Bharatbhai
    Ahmadi, Omid
    de Groot, Charles
    Sanders, James
    NEW ZEALAND MEDICAL JOURNAL, 2022, 135 (1556) : 127 - 131
  • [36] Surgical management of papillary thyroid carcinoma: an overview
    Miccoli, Paolo
    Bakkar, Sohail
    UPDATES IN SURGERY, 2017, 69 (02) : 145 - 150
  • [37] Surgical management of papillary thyroid carcinoma: an overview
    Paolo Miccoli
    Sohail Bakkar
    Updates in Surgery, 2017, 69 : 145 - 150
  • [38] Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma
    Qian, Xiaoyuan
    Wan, Junlai
    Qian, Can
    Zhang, Jiaqiao
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 7523 - 7531
  • [39] Contemporary management of papillary carcinoma of the thyroid gland
    Rosenbaum, Michael A.
    McHenry, Christopher R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (03) : 317 - 329
  • [40] An overview of the management of papillary and follicular thyroid carcinoma
    Mazzaferri, EL
    THYROID, 1999, 9 (05) : 421 - 427